Published in Ann Oncol on January 01, 2003
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer (2008) 1.50
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol (2010) 1.20
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol (2011) 1.15
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol (2012) 1.12
Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol (2006) 1.11
Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas (2013) 1.03
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer (2004) 1.00
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer (2014) 0.96
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One (2013) 0.96
Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol (2012) 0.94
Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer. Nat Rev Clin Oncol (2010) 0.93
Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.91
A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Res Treat (2012) 0.88
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer (2008) 0.88
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis (2010) 0.84
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer (2004) 0.82
Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol (2011) 0.81
Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. World J Gastroenterol (2012) 0.81
A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. PLoS One (2014) 0.79
The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. Surg Clin North Am (2015) 0.79
Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. Mol Clin Oncol (2014) 0.78
Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol (2010) 0.78
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther (2016) 0.77
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs (2015) 0.76
Advanced pancreatic cancer - how to choose an adequate treatment option. World J Gastroenterol (2015) 0.76
Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evid (2007) 0.75
Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas (2017) 0.75
Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol (2016) 0.75
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs (2015) 0.75
Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci U S A (1968) 4.07
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ (1993) 3.26
Sharing of virulence-associated properties at the phenotypic and genetic levels between enteropathogenic Escherichia coli and Hafnia alvei. J Med Microbiol (1992) 3.03
T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia (2005) 2.73
The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J (2000) 2.59
Transformation of human lymphocytes: inhibition by homologous alpha globulin. Science (1968) 2.55
Hafnia alvei, a probable cause of diarrhea in humans. Infect Immun (1991) 2.55
Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet (1987) 2.32
Import of mitochondrial carriers mediated by essential proteins of the intermembrane space. Science (1998) 2.27
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia (2006) 2.24
Early prediction of individual outcome after cardiopulmonary resuscitation. Lancet (1993) 2.21
FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity (1995) 2.19
Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc Natl Acad Sci U S A (1997) 2.14
Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J Biol Chem (1982) 2.13
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst (1998) 2.12
Mutations in GJB6 cause nonsyndromic autosomal dominant deafness at DFNA3 locus. Nat Genet (1999) 2.05
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut (2011) 1.96
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol (2004) 1.95
Determination of the primary structures of 16 asialo-carbohydrate units derived from human plasma alpha 1-acid glycoprotein by 360-MHZ 1H NMR spectroscopy and permethylation analysis. Biochemistry (1978) 1.92
Cholera epidemics in Bangladesh: 1985-1991. J Diarrhoeal Dis Res (1992) 1.92
Tn1721-encoded tetracycline resistance: mapping of structural and regulatory genes mediating resistance. J Bacteriol (1983) 1.92
Enteropathogens associated with acute and persistent diarrhea in Bangladeshi children less than 5 years of age. J Infect Dis (1992) 1.91
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg (2007) 1.85
Plasmid-mediated uptake and metabolism of sucrose by Escherichia coli K-12. J Bacteriol (1982) 1.84
Anaerobic dechlorination and degradation of hexachlorocyclohexane isomers by anaerobic and facultative anaerobic bacteria. Arch Microbiol (1977) 1.83
Survival of classic cholera in Bangladesh. Lancet (1991) 1.83
The effect of immunoregulatory globulin (IRA) upon lymphocytes in vitro. J Immunol (1972) 1.79
CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science (2000) 1.77
Heterologous repressor-operator recognition among four classes of tetracycline resistance determinants. J Bacteriol (1985) 1.76
Synthesis of a muscarinic receptor antagonist via a diastereoselective Michael reaction, selective deoxyfluorination and aromatic metal-halogen exchange reaction. J Org Chem (2001) 1.75
CTnscr94, a conjugative transposon found in enterobacteria. J Bacteriol (1997) 1.70
Nucleotide sequences and operon structure of plasmid-borne genes mediating uptake and utilization of raffinose in Escherichia coli. J Bacteriol (1989) 1.70
Isolation of an immunosuppressive peptide fraction from human plasma. J Immunol (1973) 1.70
Decomposition of 14C-labelled lignin and phenols by a Nocardia sp. Arch Microbiol (1977) 1.69
Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels. J Biol Chem (1996) 1.68
Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol (2007) 1.67
Screening for lignin degrading bacteria by means of 14C-labelled lignins. Arch Microbiol (1978) 1.65
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol (2001) 1.64
Active unfolding of precursor proteins during mitochondrial protein import. EMBO J (1997) 1.62
Repulsively bound atom pairs in an optical lattice. Nature (2006) 1.62
Function and structure of heterodimeric amino acid transporters. Am J Physiol Cell Physiol (2001) 1.60
Cyclophilin catalyzes protein folding in yeast mitochondria. Proc Natl Acad Sci U S A (1995) 1.60
Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia (2004) 1.59
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res (2001) 1.57
Tim9p, an essential partner subunit of Tim10p for the import of mitochondrial carrier proteins. EMBO J (1998) 1.55
'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol (2006) 1.54
CD66-mediated phagocytosis of Opa52 Neisseria gonorrhoeae requires a Src-like tyrosine kinase- and Rac1-dependent signalling pathway. EMBO J (1998) 1.53
Cell volume in the regulation of hepatic function: a mechanism for metabolic control. Biochim Biophys Acta (1991) 1.51
Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem (1997) 1.51
The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux. J Neurochem (1999) 1.50
Similar metabolic responses to standardized total parenteral nutrition of septic and nonseptic critically ill patients. Am J Clin Nutr (2001) 1.49
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer (2003) 1.48
Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell (1997) 1.47
Competitive blockade of lymphocyte stimulation by a serum immuno-regulatory alpha globulin (IRA). Transplant Proc (1969) 1.47
Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis (1980) 1.46
Role of N-linked glycosylation in rat renal Na/Pi-cotransport. J Biol Chem (1994) 1.46
Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: parallels between pathogen accommodation and mitochondrial endosymbiosis. Cell (1996) 1.44
Synaptic vesicles: selective depletion in crayfish excitatory and inhibitory axons. Science (1972) 1.44
Raffinose metabolism in Escherichia coli K12. Purification and properties of a new alpha-galactosidase specified by a transmissible plasmid. Eur J Biochem (1976) 1.44
Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh. J Infect Dis (1985) 1.43
Inheritance of human alpha-1-acid glycoprotein (orosomucoid) variants. J Clin Invest (1969) 1.43
Fat elimination in acute renal failure: long-chain vs medium-chain triglycerides. Am J Clin Nutr (1992) 1.42
Immunosuppression by human plasma alpha 1-acid glycoprotein: importance of the carbohydrate moiety. Proc Natl Acad Sci U S A (1980) 1.41
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie (2003) 1.41
[Cardiovascular diseases caused by unemployment? An analysis from the viewpoint of social medicine]. Wien Klin Wochenschr (1997) 1.40
Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett (1996) 1.40
Three new restriction endonucleases MaeI, MaeII and MaeIII from Methanococcus aeolicus. Nucleic Acids Res (1984) 1.39
Cellular hydration state: an important determinant of protein catabolism in health and disease. Lancet (1993) 1.38
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol (1997) 1.38
Role of KCNE1-dependent K+ fluxes in mouse proximal tubule. J Am Soc Nephrol (2001) 1.38
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie (2003) 1.38
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology (1999) 1.38
The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer (1998) 1.38
Hydrazinolysis of alpha-1-acid glycoprotein. Biochim Biophys Acta (1966) 1.36
Evidence for a bicarbonate leak in the proximal tubule of the rat kidney. Pflugers Arch (1980) 1.36
Palliative chemotherapy for advanced gastric cancer. Ann Oncol (2004) 1.36
Differentiation of Shigella flexneri strains by rRNA gene restriction patterns. J Clin Microbiol (1992) 1.35